IRIS
DI GIACOMO, ANNA MARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.476
EU - Europa 6.625
AS - Asia 5.699
SA - Sud America 1.247
AF - Africa 327
OC - Oceania 14
Totale 22.388
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.301
SG - Singapore 2.177
RU - Federazione Russa 1.854
CN - Cina 1.397
IT - Italia 1.321
BR - Brasile 1.027
IE - Irlanda 980
VN - Vietnam 775
GB - Regno Unito 673
HK - Hong Kong 511
FR - Francia 417
DE - Germania 332
SE - Svezia 285
KR - Corea 241
ZA - Sudafrica 219
UA - Ucraina 186
FI - Finlandia 179
IN - India 154
NL - Olanda 116
ES - Italia 94
AR - Argentina 83
MX - Messico 75
BD - Bangladesh 72
CA - Canada 68
EC - Ecuador 46
AT - Austria 42
IQ - Iraq 42
PL - Polonia 39
KE - Kenya 35
ID - Indonesia 34
JP - Giappone 33
TR - Turchia 32
SA - Arabia Saudita 23
CO - Colombia 19
AZ - Azerbaigian 18
PK - Pakistan 18
CL - Cile 17
IR - Iran 16
AE - Emirati Arabi Uniti 15
PY - Paraguay 15
UZ - Uzbekistan 15
JO - Giordania 14
VE - Venezuela 14
AL - Albania 13
MA - Marocco 13
MY - Malesia 13
AU - Australia 12
BE - Belgio 12
PE - Perù 12
PH - Filippine 12
NG - Nigeria 11
DZ - Algeria 10
LT - Lituania 10
NP - Nepal 10
CH - Svizzera 9
EG - Egitto 9
KZ - Kazakistan 9
KG - Kirghizistan 8
LB - Libano 8
TN - Tunisia 8
BH - Bahrain 7
BO - Bolivia 7
OM - Oman 7
CZ - Repubblica Ceca 6
ET - Etiopia 6
NO - Norvegia 6
TH - Thailandia 6
UY - Uruguay 6
BG - Bulgaria 5
BY - Bielorussia 5
DK - Danimarca 5
DO - Repubblica Dominicana 5
JM - Giamaica 5
PT - Portogallo 5
SV - El Salvador 5
EE - Estonia 4
IL - Israele 4
PA - Panama 4
SK - Slovacchia (Repubblica Slovacca) 4
AM - Armenia 3
AO - Angola 3
BA - Bosnia-Erzegovina 3
CI - Costa d'Avorio 3
CR - Costa Rica 3
GR - Grecia 3
HN - Honduras 3
HU - Ungheria 3
KH - Cambogia 3
LK - Sri Lanka 3
LV - Lettonia 3
MD - Moldavia 3
RO - Romania 3
SY - Repubblica araba siriana 3
TT - Trinidad e Tobago 3
CG - Congo 2
GA - Gabon 2
GE - Georgia 2
GT - Guatemala 2
HR - Croazia 2
KW - Kuwait 2
Totale 22.362
Salva come PNG Salva come JPEG
Città #
Dallas 1.529
Singapore 1.303
Dublin 975
Fairfield 817
Ashburn 622
Santa Clara 527
Moscow 519
Hong Kong 489
Southend 453
Woodbridge 399
Hefei 380
Beijing 369
San Jose 355
Seattle 348
Houston 316
Cambridge 299
Wilmington 292
Siena 268
Ho Chi Minh City 248
Seoul 232
Milan 201
Johannesburg 198
Lauterbourg 183
Princeton 170
The Dalles 163
Jacksonville 159
Council Bluffs 148
Los Angeles 148
Hanoi 135
Ann Arbor 134
Florence 121
New York 120
Chandler 117
Helsinki 113
Dong Ket 101
San Mateo 84
Shanghai 83
São Paulo 80
Rome 73
Amsterdam 67
Dearborn 66
Málaga 54
Bengaluru 51
Redondo Beach 51
Nuremberg 49
San Diego 47
Buffalo 46
Lappeenranta 43
Munich 42
Chicago 41
London 40
Frankfurt am Main 37
Rio de Janeiro 36
Orem 35
Denver 31
Haiphong 30
Stockholm 30
Tokyo 30
Warsaw 30
Brooklyn 29
Montreal 29
Guangzhou 27
San Francisco 27
Vienna 27
Chennai 26
Nanjing 26
Da Nang 24
Phoenix 23
Belo Horizonte 21
Manchester 21
Mexico City 21
Portsmouth 21
Guayaquil 20
Bologna 18
Borgo San Lorenzo 17
Düsseldorf 17
Naples 17
Perugia 17
Poplar 17
Toronto 17
Atlanta 16
Baku 16
Boardman 16
Cascina 16
Fremont 16
Ninh Bình 15
Tianjin 15
Turku 15
Brasília 14
Curitiba 14
Empoli 14
Barnet 13
Dhaka 13
Palermo 13
Porto Alegre 13
Quito 13
Tashkent 13
Baghdad 12
Biên Hòa 12
Boston 12
Totale 14.870
Salva come PNG Salva come JPEG
Nome #
Neurological adverse events of ICI therapy: A ten-year comprehensive management from a multidisciplinary team 472
Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy) 342
Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme 327
Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: Results of a phase II study 313
Immunomodulatory properties of DNA hypomethylating agents: Selecting the optimal epigenetic partner for cancer immunotherapy 253
Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy 252
Adjuvant vemurafenib in resected, BRAF V600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial 245
Circulating levels of PD-L1 in mesothelioma patients from the NIBIT-MESO-1 study: Correlation with survival 243
Ipilimumab in pretreated metastatic uveal melanoma patients: safety and clinical efficacy 242
A Multidisciplinary Approach to Improve the Management of Immune-Checkpoint Inhibitor-Related Pneumonitis 236
A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation 221
Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab 220
Guadecitabine plus ipilimumab in unresectable melanoma: the NIBIT-M4 clinical trial 218
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial 217
Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy. 216
“Cancer Bio-Immunotherapy in Siena”: Thirteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 8–10, 2015 210
Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches 208
Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/ mismatch repair–deficient cancer: results from the phase II KEYNOTE-158 study 207
Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models 206
Back to simplicity: A four-marker blood cell score to quantify prognostically relevant myeloid cells in melanoma patients 206
Association between Immune-Related Adverse Events and Recurrence-Free Survival among Patients with Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial 203
Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases 202
Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme 198
Ipilmumab in the daily practice: feasibility, safety, efficacy and long term follow-up in heavily pretreated metastatic melanoma patients 196
The italian experience on the feasibility and safety of ipilmumab therapy in pretracted metastatic melanoma patients 195
“Cancer Bio-Immunotherapy in Siena”: Eleventh Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 17–19, 2013 190
Epigenetic immune remodeling of mesothelioma cells: A new strategy to improve the efficacy of immunotherapy 189
Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients 186
Brief Communication PD1-related Nephrotoxicity: Optimizing Its Clinical Management Through Histopathologic Features 185
Ipilimumab in the common daily practice: feasibility, safety, efficacy and long-term follow-up in heavily pretreated metastatic melanoma patients 184
Expression and regulation of B7-H3 immunoregulatory receptor, in human mesothelial and mesothelioma cells: immunotherapeutic implications 183
Rational Use of Monoclonal Antibodies as Therapeutic Treatment in an Oncologic Patient with Long COVID 180
Baseline serum TSH levels predict the absence of thyroid dysfunction in cancer patients treated with immunotherapy 179
A novel microRNA signature for the detection of melanoma by liquid biopsy 178
Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial 173
Immunotherapy targeting immune check-point(s) in brain metastases 173
Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study 173
A Phase II Study Combining Ipilimumab and Fotemustine in Patients With Metastatic Melanoma - the NIBIT-M1 Trial 170
Landscape of immune-related signatures induced by targeting of different epigenetic regulators in melanoma: implications for immunotherapy 167
SARS-CoV-2 infection in cancer patients on active therapy after the booster dose of mRNA vaccines 166
Clinical Efficacy of the Anti-Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) Monoclonal Antibody Ipilimumab in Pretreated Metastatic Uveal Melanoma Patients 166
Predictors of responses to immune checkpoint blockade in advanced melanoma 166
Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab 166
The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications 161
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian network for tumor biotherapy (NIBIT)-M1 phase II study 161
Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab 159
Molecular pathways: At the crossroads of cancer epigenetics and immunotherapy 158
Tenth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), SIENA, Italy, November 5-7, 2012 157
Ipilimumab in the common daily practice: Feasibility, safety, and efficacy in heavily pretreated metastatic melanoma patients 156
The future of targeting cytotoxic T-lymphocyte-associated protein-4: Is there a role? 153
A phase Ib study combining the second-generation DNA hypomethylating agent (DHA) guadecitabine (SGI-110) and ipilimumab in patients with metastatic melanoma: the NIBIT-M4 Study. 153
Primary hepatic epithelioid hemangioendothelioma progressively responsive to interferon-alpha: is there room for novel anti-angiogenetic treatments? 152
A novel method for monitoring response to chemotherapy based on the detection of circulating cancer cells: A case report 149
Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria 148
Perspectives on the role of “-Omics” in predicting response to immunotherapy 148
Thymosin α1 in melanoma: from the clinical trial setting to the daily practice and beyond 148
Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: Comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells 147
Successful Targeting of CTLA-4 in a Melanoma Clinical Case: A Long-Term “One Stop Therapeutic Shop” 146
Challenges in lung cancer therapy during the COVID-19 pandemic 146
Correction to: Predictive value of perilesional edema volume in melanoma brain metastasis response to stereotactic radiosurgery (Journal of Neuro-Oncology, (2024), 10.1007/s11060-024-04818-9) 144
Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis 142
Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases 140
Italian nivolumab Expanded Access Programme in melanoma adjuvant setting: patient outcomes and safety profile 139
Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma 139
Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications 139
Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915) 138
Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era 138
Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma 136
Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial 134
Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients 134
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial 133
Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients 133
Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study 133
Ipilmumab in pretreated metastatic uveal melanoma patiens; safety and clinical efficacy 132
Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial 131
Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial 131
Can epigenetics have a clinical impact in the treatment of melanoma? 130
Survival Outcomes in Patients with Previously Untreated BRAF Wild-Type Advanced Melanoma Treated with Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial 129
Brain metastasis in melanoma: clinical activity of CTLA-4 antibody therapy 129
Nivolumab plus ipilimumab in melanoma brain metastases 129
Epigenetics meets immune checkpoints 128
Long-term follow-up of a papillary tumor of the pineal region: addendum to a case report 128
Efficacy of ipilimumab plus nivolumab or ipilimumab plus fotemustine vs fotemustine in patients with melanoma metastatic to the brain: Primary analysis of the phase III NIBIT-M2 trial 125
The Italian experience on the feasibility and safety of ipilimumab therapy in pretreated metastatic melanoma patients 124
Safety and immunobiological activity of guadecitabine sequenced with ipilimumab in metastatic melanoma patients: The phase Ib NIBIT-M4 study 122
Predictive value of perilesional edema volume in melanoma brain metastasis response to stereotactic radiosurgery 121
Adjuvant nivolumab for stage III/IV melanoma: Evaluation of safety outcomes and association with recurrence-free survival 121
Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial 120
From Co-Stimulation to Co-Inhibition: A Continuum of Immunotherapy Care Toward Long-Term Survival in Melanoma 120
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238 119
Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream 117
Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma 117
Effects of molecular heterogeneity on survival of patients with BRAFV600-mutated melanoma treated with vemurafenib with or without cobimetinib in the coBRIM study 116
Mutational concordance between primary and metastatic melanoma: A next-generation sequencing approach 116
Severe acute respiratory syndrome coronavirus 2 vaccination and cancer therapy: A successful but mindful mix 116
Serum lactate dehydrogenase as a prognostic marker for treatment response in IDH wild-type glioblastoma patients undergoing stupp protocol 116
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial 115
Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: immunotherapeutic implications 115
Dietary compounds and cutaneous malignant melanoma: Recent advances from a biological perspective 115
Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma 114
Totale 16.882
Salva come PNG Salva come JPEG
Categoria #
all - tutte 75.357
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 75.357
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021443 0 0 0 0 0 0 0 0 0 165 59 219
2021/2022989 43 87 91 20 18 65 34 42 74 137 123 255
2022/20231.326 106 86 212 113 58 235 42 67 92 56 219 40
2023/20241.661 63 62 152 61 49 393 551 62 44 24 38 162
2024/20254.287 121 148 319 234 459 278 139 175 479 323 455 1.157
2025/202610.439 790 1.430 1.420 1.350 2.273 396 1.221 468 399 692 0 0
Totale 23.014